Loading
Olatorepatide / Overweight Or Obesity · Phase 2 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration studying olatorepatide, a novel agent for overweight and obesity without diabetes, with planned enrollment of 360 participants and follow-up to approximately 60 weeks. The study is currently recruiting and has not yet reported results; it is designed to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy on body weight change.
Phase 2, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Overweight or Obesity; age from 18 Years. Intervention: Olatorepatide arm 1; Olatorepatide arm 2; Olatorepatide arm 3; Olatorepatide arm 4; Olatorepatide arm 5. Compared with: Matching Placebo arm 6 — Active Comparator. n = 360. 5 sites: United States.
This is a Phase 2 trial registration studying olatorepatide, a novel agent for overweight and obesity without diabetes, with planned enrollment of 360 participants and follow-up to approximately 60 weeks. The study is currently recruiting and has not yet reported results; it is designed to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy on body weight change.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This trial is in the recruitment phase and will provide Phase 2 evidence on the safety, tolerability, and dose-response of olatorepatide in a non-diabetic overweight/obesity population. Results are not yet available and should not be inferred from this registry record.
This is a Phase 2 interventional trial registration with planned enrollment of 360 participants, currently recruiting, designed to assess safety, tolerability, and preliminary efficacy of olatorepatide in overweight/obesity without diabetes; no results are yet reported.
As stated by the source record.
Quoted from the source exactly as published.
This trial is in the recruitment phase and will provide Phase 2 evidence on the safety, tolerability, and dose-response of olatorepatide in a non-diabetic overweight/obesity population. Results are not yet available and should not be inferred from this registry record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07685808). This is a study registration, not published results. Lead sponsor: Regeneron Pharmaceuticals. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 360 participants (ESTIMATED). Conditions: Overweight or Obesity. Interventions: DRUG: Olatorepatide; DRUG: Placebo. Primary outcome measures: Occurrence of Treatment-Emergent Adverse Events (TEAEs) , Up to approximately 60 weeks; Severity of TEAEs , Up to approximately 60 weeks; Percent change in body weight , From baseline to week 52. Brief summary: This study will test an experimental drug called olatorepatide ("study drug") to determine how safe and effective this drug is compared to placebo and how easily the body can accept this drug at different doses and dosing schedules without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity but do not have diabetes. The study is looking at: * What side effects the study drug might cause * How much study drug is in the blood at different times * How well the study drug works * What effects the study drug may have on the body at different dosing schedules * If the body makes antibodies to the study drug as this may cause the study drug to not work as well
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.